The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs

J. M. Michot, C. Bigenwald

Résultats de recherche: Contribution à un journal › Editorial

Accès au document

@article{72ac983f83164ccda310d0e3ac8f0953,

title = "The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs",

author = "Michot, {J. M.} and C. Bigenwald",

year = "2025",

month = jul,

day = "1",

doi = "10.1016/j.annonc.2025.04.008",

language = "English",

volume = "36",

pages = "711",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "7",

}

TY - JOUR

T1 - The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs

AU - Michot, J. M.

AU - Bigenwald, C.

PY - 2025/7/1

Y1 - 2025/7/1

UR - http://www.scopus.com/inward/record.url?scp=105006739287&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2025.04.008

DO - 10.1016/j.annonc.2025.04.008

M3 - Editorial

C2 - 40288677

AN - SCOPUS:105006739287

SN - 0923-7534

VL - 36

SP - 711

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -